FDA rejects Immunomedics breast cancer drug, extending long regulatory drought
Immunomedics' antibody drug conjugate to treat women with an aggressive form of breast cancer could not be approved at this time, the FDA said.
The 37-year drug development drought lives on.
Immunomedics (), the biotech founded in 1982, was informed by the Food and Drug Administration on
